Sagimet Biosciences (SGMT) Q1 2026 earnings summary

Executive summary

• Lead drug candidate denifanstat met all primary and secondary endpoints in Phase 3 acne trials in China and showed favorable long-term safety; NDA accepted by China NMPA in December 2025.

• Strategic focus shifted to dermatology, with plans to initiate a Phase 3 trial of denifanstat for moderate to severe acne in the U.S. in the second half of 2026.

• TVB-3567, a second FASN inhibitor, is in Phase 1 trials for acne, with Phase 2 planned for late 2026.

• Combination program of denifanstat and resmetirom for MASH is Phase 2-ready, pending non-dilutive financing.

• Secured $175M in equity financing in April 2026, strengthening the ability to fund operations through 2028.

Financial highlights

• Net loss for Q1 2026 was $10.7 million, a 41% improvement from $18.2 million in Q1 2025.

• Operating expenses decreased 41% year-over-year to $11.7 million, driven by a 54% reduction in R&D expenses.

• Research and development expense was $7.0M for Q1 2026, down from $15.3M in Q1 2025.

• Cash, cash equivalents, and marketable securities totaled $104.5 million as of March 31, 2026.

• Net cash used in operating activities was $8.6 million for Q1 2026, down from $14.5 million in Q1 2025.

Outlook and guidance

• Plans to file IND for denifanstat in US acne indication mid-2026 and initiate Phase 3 trial in H2 2026, pending IND clearance.

• Current cash position and recent financing expected to fund operations and clinical milestones through 2028, including denifanstat Phase 3 data readout.

• No further MASH clinical development until additional non-dilutive funding is secured.

• Anticipates developing a topical FASN inhibitor for acne.